Title: | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer |
Authors: | Komatsu, Yoshito Browse this author →KAKEN DB |
Yuki, Satoshi Browse this author |
Sogabe, Susumu Browse this author |
Fukushima, Hiraku Browse this author |
Nakatsumi, Hiroshi Browse this author |
Kobayashi, Yoshimitsu Browse this author |
Iwanaga, Ichiro Browse this author |
Nakamura, Michio Browse this author |
Hatanaka, Kazuteru Browse this author |
Miyagishima, Takuto Browse this author |
Kudo, Mineo Browse this author |
Munakata, Masaki Browse this author |
Meguro, Takashi Browse this author |
Tateyama, Miki Browse this author |
Sakata, Yuh Browse this author |
Issue Date: | Sep-2012 |
Publisher: | Informa Healthcare |
Journal Title: | Acta Oncologica |
Volume: | 51 |
Issue: | 7 |
Start Page: | 867 |
End Page: | 872 |
Publisher DOI: | 10.3109/0284186X.2012.682629 |
PMID: | 22554343 |
Abstract: | Background. In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI. We previously reported that IRIS is also effective as first-line treatment. Patients and Methods. Eligibility criteria included inoperable recurrent colorectal cancer with a confirmed diagnosis of adenocarcinoma, age ≥ 20 years, and no history of prior chemotherapy. S-1 (40-60 mg twice daily) was given orally on days 1 to 14, and irinotecan (100 mg/m2) and bevacizumab (5 mg/kg) were given intravenously on days 1 and 15 of a 28-day cycle. The primary endpoint was safety. The secondary endpoints included overall response (OR), progression-free survival (PFS), and overall survival (OS). Results. A total of 52 eligible patients were enrolled from October 2007 through March 2009. In safety analysis, the incidences of grade 3 or 4 adverse reactions were as follows: neutropenia, 27%; hypertension, 21%; and diarrhea, 17%. The overall response rate was 57.7%. Median progression-free survival was 16.7 months. Conclusion. IRIS plus bevacizumab is a well-tolerated, highly effective chemotherapeutic regimen that is easy to administer. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/53168 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|